CVRx Inc Aktie News

MINNEAPOLIS, May 28, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 202...

CVRx, Inc. (NASDAQ:CVRX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Kevin Hykes - President & CEO Jared Oasheim - CFO Mike Vallie - IR, ICR Healthcare Conference Call Participants Macauley Kilbane - William Blair Nelson Cox - Lake Street Capital Markets Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald Operator Good day, everyone...

MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.

CVRx Inc. stock has recently dropped 40%, presenting a buying opportunity as the long-term growth potential remains intact. Barostim has strong clinical results and significant market potential, with a $2.2 billion TAM. Average selling prices can potentially improve as the market recognizes Barostim's effectiveness.

First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024 First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024

New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstr...

CVRx, Inc. (NASDAQ:CVRX ) Q4 2024 Earnings Conference Call February 4, 2025 4:30 PM ET Company Participants Mike Vallie - Investor Relations, ICR Healthcare Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Rohin Patel - JPMorgan Macauley Kilbane - William Blair William Plovanic - Canaccord Genuity Samantha Munoz - Piper Sandl...

MINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2024.